Literature DB >> 27078681

Diaphorase Coupling Protocols for Red-Shifting Dehydrogenase Assays.

Mindy I Davis1, Min Shen1, Anton Simeonov1, Matthew D Hall1.   

Abstract

Dehydrogenases are an important target for the development of cancer therapeutics. Dehydrogenases either produce or consume NAD(P)H, which is fluorescent but at a wavelength where many compounds found in chemical libraries are also fluorescent. By coupling dehydrogenases to diaphorase, which utilizes NAD(P)H to produce the fluorescent molecule resorufin from resazurin, the assay can be red-shifted into a spectral region that reduces interference from compound libraries. Dehydrogenases that produce NAD(P)H, such as isocitrate dehydrogenase 1 (IDH1), can be read in kinetic mode. Dehydrogenases that consume NAD(P)H, such as mutant IDH1 R132H, can be read in endpoint mode. Here, we report protocols for robust and miniaturized 1,536-well assays for WT IDH1 and IDH1 R132H coupled to diaphorase, and the counterassays used to further detect compound interference with the coupling reagents. This coupling technique is applicable to dehydrogenases that either produce or consume NAD(P)H, and the examples provided here can act as guidelines for the development of high-throughput screens against this enzyme class.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27078681      PMCID: PMC4840998          DOI: 10.1089/adt.2016.706

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  12 in total

Review 1.  Aldehyde dehydrogenases and cancer stem cells.

Authors:  Xia Xu; Shoujie Chai; Pingli Wang; Chenchen Zhang; Yiming Yang; Ying Yang; Kai Wang
Journal:  Cancer Lett       Date:  2015-08-28       Impact factor: 8.679

2.  Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries.

Authors:  James Inglese; Douglas S Auld; Ajit Jadhav; Ronald L Johnson; Anton Simeonov; Adam Yasgar; Wei Zheng; Christopher P Austin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

3.  Compound Management for Quantitative High-Throughput Screening.

Authors:  Adam Yasgar; Paul Shinn; Ajit Jadhav; Douglas Auld; Sam Michael; Wei Zheng; Christopher P Austin; James Inglese; Anton Simeonov
Journal:  JALA Charlottesv Va       Date:  2008-04

4.  Fluorescence spectroscopic profiling of compound libraries.

Authors:  Anton Simeonov; Ajit Jadhav; Craig J Thomas; Yuhong Wang; Ruili Huang; Noel T Southall; Paul Shinn; Jeremy Smith; Christopher P Austin; Douglas S Auld; James Inglese
Journal:  J Med Chem       Date:  2008-03-26       Impact factor: 7.446

5.  Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo.

Authors:  Janeta Popovici-Muller; Jeffrey O Saunders; Francesco G Salituro; Jeremy M Travins; Shunqi Yan; Fang Zhao; Stefan Gross; Lenny Dang; Katharine E Yen; Hua Yang; Kimberly S Straley; Shengfang Jin; Kaiko Kunii; Valeria R Fantin; Shunan Zhang; Qiongqun Pan; Derek Shi; Scott A Biller; Shinsan M Su
Journal:  ACS Med Chem Lett       Date:  2012-09-17       Impact factor: 4.345

6.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

7.  A new assay for diaphorase activity in reagent formulations, based on the reduction of thiazolyl blue.

Authors:  R S Boethling; T L Weaver
Journal:  Clin Chem       Date:  1979-12       Impact factor: 8.327

8.  Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.

Authors:  Mindy I Davis; Stefan Gross; Min Shen; Kimberly S Straley; Rajan Pragani; Wendy A Lea; Janeta Popovici-Muller; Byron DeLaBarre; Erin Artin; Natasha Thorne; Douglas S Auld; Zhuyin Li; Lenny Dang; Matthew B Boxer; Anton Simeonov
Journal:  J Biol Chem       Date:  2014-03-25       Impact factor: 5.157

Review 9.  Avoiding Fluorescence Assay Interference-The Case for Diaphorase.

Authors:  Matthew D Hall; Anton Simeonov; Mindy I Davis
Journal:  Assay Drug Dev Technol       Date:  2016-04       Impact factor: 1.738

Review 10.  IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.

Authors:  Hui Yang; Dan Ye; Kun-Liang Guan; Yue Xiong
Journal:  Clin Cancer Res       Date:  2012-10-15       Impact factor: 13.801

View more
  9 in total

1.  Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH).

Authors:  Ganesha Rai; Kyle R Brimacombe; Bryan T Mott; Daniel J Urban; Xin Hu; Shyh-Ming Yang; Tobie D Lee; Dorian M Cheff; Jennifer Kouznetsova; Gloria A Benavides; Katie Pohida; Eric J Kuenstner; Diane K Luci; Christine M Lukacs; Douglas R Davies; David M Dranow; Hu Zhu; Gary Sulikowski; William J Moore; Gordon M Stott; Andrew J Flint; Matthew D Hall; Victor M Darley-Usmar; Leonard M Neckers; Chi V Dang; Alex G Waterson; Anton Simeonov; Ajit Jadhav; David J Maloney
Journal:  J Med Chem       Date:  2017-11-09       Impact factor: 7.446

Review 2.  Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs.

Authors:  Nathan P Coussens; John C Braisted; Tyler Peryea; G Sitta Sittampalam; Anton Simeonov; Matthew D Hall
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

3.  A new non-radioactive deoxyhypusine synthase assay adaptable to high throughput screening.

Authors:  Myung Hee Park; Ajeet Mandal; Swati Mandal; Edith C Wolff
Journal:  Amino Acids       Date:  2017-08-17       Impact factor: 3.520

4.  Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors.

Authors:  Jason M Rohde; Kyle R Brimacombe; Li Liu; Michael E Pacold; Adam Yasgar; Dorian M Cheff; Tobie D Lee; Ganesha Rai; Bolormaa Baljinnyam; Zhuyin Li; Anton Simeonov; Matthew D Hall; Min Shen; David M Sabatini; Matthew B Boxer
Journal:  Bioorg Med Chem       Date:  2018-02-27       Impact factor: 3.641

Review 5.  Avoiding Fluorescence Assay Interference-The Case for Diaphorase.

Authors:  Matthew D Hall; Anton Simeonov; Mindy I Davis
Journal:  Assay Drug Dev Technol       Date:  2016-04       Impact factor: 1.738

6.  A High-Content Assay Enables the Automated Screening and Identification of Small Molecules with Specific ALDH1A1-Inhibitory Activity.

Authors:  Adam Yasgar; Steven A Titus; Yuhong Wang; Carina Danchik; Shyh-Ming Yang; Vasilis Vasiliou; Ajit Jadhav; David J Maloney; Anton Simeonov; Natalia J Martinez
Journal:  PLoS One       Date:  2017-01-27       Impact factor: 3.240

7.  Discovery and Characterization of a Novel Allosteric Small-Molecule Inhibitor of NADP+-Dependent Malic Enzyme 1.

Authors:  Tomohiro Yoshida; Tetsuhiro Kawabe; Lewis C Cantley; Costas A Lyssiotis
Journal:  Biochemistry       Date:  2022-07-12       Impact factor: 3.321

8.  Identification of Activators of Human Fumarate Hydratase by Quantitative High-Throughput Screening.

Authors:  Hu Zhu; Olivia W Lee; Pranav Shah; Ajit Jadhav; Xin Xu; Samarjit Patnaik; Min Shen; Matthew D Hall
Journal:  SLAS Discov       Date:  2019-09-14       Impact factor: 3.341

9.  Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays.

Authors:  Daniel J Urban; Natalia J Martinez; Mindy I Davis; Kyle R Brimacombe; Dorian M Cheff; Tobie D Lee; Mark J Henderson; Steven A Titus; Rajan Pragani; Jason M Rohde; Li Liu; Yuhong Fang; Surendra Karavadhi; Pranav Shah; Olivia W Lee; Amy Wang; Andrew McIver; Hongchao Zheng; Xiaodong Wang; Xin Xu; Ajit Jadhav; Anton Simeonov; Min Shen; Matthew B Boxer; Matthew D Hall
Journal:  Sci Rep       Date:  2017-10-06       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.